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Introduction
The interface between the compact bone and the bone
marrow (BM), the endosteum, is a privileged site where
bone formation and turnover take place. In the past decade,
it has emerged that this endosteal region of the BM, particu-
larly the metaphyseal spongiosa rich in trabecular bone, har-
bors the most primitive hematopoietic stem cells (HSC) able
to reconstitute long-term multi-lineage hematopoiesis upon
serial transplantation into lethally irradiated mice.1-5 Hence,
it was concluded that HSC niches are not distributed ran-
domly in the BM tissue but preferentially locate within 2-3
cell diameters from endosteal bone surfaces.3-4 These conclu-
sions were further supported by the observation that HSC
express calcium receptors sensing the calcium gradient
formed by osteoclast-mediated bone degradation and help-
ing HSC to lodge in these endosteal niches.6 This drew the
attention to the potential role of osteoblasts, osteoprogeni-
tors and their mesenchymal precursors in regulating most
primitive HSC. Conditional gene deletion in, and specific
ablation of osteoblasts,7 osteoprogenitors8 or mesenchymal
stem cells9 have shown that osteoblast-lineage and mes-
enchymal progenitor cells are critical to maintain normal
HSC within the BM. It has also recently emerged that in
addition to regulating HSC, osteoblasts and their progenitors
critically regulate medullar B lymphopoiesis. Indeed, abla-
tion of osteoblasts or conditional deletion of the Gsα gene
specifically in osteoblasts impairs primitive B lymphopoiesis
in the BM.10-11 Therefore, osteoblastic lineage cells at the
endosteum control the maintenance of two different arms of
hematopoiesis: 1) primitive hematopoiesis via HSC; and 2)
B-lymphopoiesis.
We and others have previously reported that specific popu-
lations of BM macrophages are critical to maintain HSC
within their BM niches. Indeed, ablation of these
macrophages12 and/or their stimulation by granulocyte
colony-stimulating factor (G-CSF)13 results in inhibition of
bone formation, disappearance of endosteal osteoblasts, and
impairment of HSC niche function as measured by expres-
sion of HSC-supportive factors such as CXCL12, Kit ligand,
angiopoietin-1, and VCAM-1, leading to robust mobilization
of HSC into the peripheral blood.12-14 We identified two
macrophage subsets that potentially exert this regulatory
role: 1) osteomacs, a specific population of BM macrophages
that form a canopy over active osteoblasts at the endosteum
and are necessary to maintain osteoblast function; and 2)
CD11b+F4/80+Ly6-G+ macrophages.15 It is still unclear as to
whether osteomacs are a subset of the CD11b+F4/80+Ly6-G+
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Osteoblasts are necessary to B lymphopoiesis and mobilizing doses of G-CSF or cyclophosphamide inhibit
osteoblasts, whereas AMD3100/Plerixafor does not. However, the effect of these mobilizing agents on B lym-
phopoiesis has not been reported. Mice (wild-type, knocked-out for TNF-α and TRAIL, or over-expressing Bcl-2)
were mobilized with G-CSF, cyclophosphamide, or AMD3100. Bone marrow, blood, spleen and lymph node con-
tent in B cells was measured. G-CSF stopped medullar B lymphopoiesis with concomitant loss of B-cell colony-
forming units, pre-pro-B, pro-B, pre-B and mature B cells and increased B-cell apoptosis by an indirect mechanism.
Overexpression of the anti-apoptotic protein Bcl2 in transgenic mice rescued B-cell colony forming units and pre-
pro-B cells in the marrow, and prevented loss of all B cells in marrow, blood and spleen. Blockade of endogenous
soluble TNF-α with Etanercept, or combined deletion of the TNF-α and TRAIL genes did not prevent B lym-
phopoiesis arrest in response to G-CSF. Unlike G-CSF, treatments with cyclophosphamide or AMD3100 did not
suppress B lymphopoiesis but caused instead robust B-cell mobilization. G-CSF, cyclophosphamide and
AMD3100 have distinct effects on B lymphopoiesis and B-cell mobilization with: 1) G-CSF inhibiting medullar B
lymphopoiesis without mobilizing B cells in a mechanism distinct from the TNF-α-mediated loss of B lym-
phopoiesis observed during inflammation or viral infections; 2) CYP mobilizing B cells but blocking their matura-
tion; and 3) AMD3100 mobilizing B cells without affecting B lymphopoiesis. These results suggest that blood
mobilized with these three agents may have distinct immune properties. 
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macrophages that specifically support osteoblasts or
whether these are separate populations. Nevertheless, we
and others have found that continuous treatment with
the cytokine G-CSF causes HSC mobilization by deplet-
ing these niche-supportive macrophages, causing deple-
tion of endosteal osteoblasts, and reducing HSC niche
function leading to HSC mobilization into the peripheral
blood.13,15 We have also found that the alkylating agent
cyclophosphamide (CYP) also depletes osteomacs and
osteoblasts from endosteal surfaces leading to impair-
ment of HSC niches and HSC mobilization.16 In contrast,
the CXCR4 antagonist AMD3100 (Plerixafor), which
mobilizes HSC by binding directly to CXCR4 and block-
ing the chemotactic signaling elicited by the binding of
the chemokine CXCL12,17 has no effect on osteoblasts or
niche-supportive macrophages.16
Considering that both G-CSF and CYP inhibit
osteoblasts and HSC niches, whereas AMD3100 does
not,16 and that endosteal osteoblasts are critical to main-
tain medullar B lymphopoiesis,10-11 we have evaluated the
effect of these three mobilizing agents on B lymphopoiesis
in the mouse.
Design and Methods
All experiments were approved by the Animal Experimentation
Ethics Committees of the University of Queensland and
University of Sydney, Australia.
Mouse mobilization and tissue harvesting
All experiments were performed on 8-12 week-old male
C57BL/6 mice. vavBcl2 transgenic mice18 were produced by breed-
ing transgenic males with wild-type C57BL/6 females. B6.TNFa–/–
mice19 were crossed with B6.TRAIL–/–mice20 to generate mice het-
erozygous for both alleles. These were interbred to yield
B6.TNFa–/–.TRAIL–/– (B6.TT) mice defective in both alleles. Pups
were identified by PCR on ear punch biopsy using primers specific
to the Bcl2 transgenene as described.18 Polymerase chain reaction
(PCR) detection of TNF-α and TRAIL wild-type and targeted alle-
les was performed essentially as described previously20 but using
TRAIL gene specific neomycin-target allele primers.
Recombinant human G-CSF (Filgrastim, Amgen, Thousand
Oaks, CA, USA) was injected twice daily subcutaneously at 125
mg/kg per injection for up to six consecutive days. Control mice
were injected with an equivalent volume of saline.  In some exper-
iments, 20 mg/kg/day etanercept was injected once daily intraperi-
toneally for four days to block endogenous soluble tumor-necrosis
factor (TNF)-α21 and G-CSF administered for the last three days of
the experiment, as described above.
Cyclophosphamide (CYP)-treated mice were injected intraperi-
toneally with a single dose of 200 mg/kg CYP diluted in saline.
AMD3100 octohydrochloride (Tocris Bioscience, Bristol, UK)
was injected intraperitoneally as a single 16 mg/kg dose correspon-
ding to 10 mg/kg of AMD3100 base. Tissues were harvested 1 h
after AMD3100 administration.
At specified time points, mice were anesthetized with isofluo-
rane and approximately 1 mL of blood collected into heparinized
tubes by cardiac puncture before cervical dislocation. Femoral BM
was flushed and spleens dissociated in phosphate-buffered saline
(PBS) containing 2% fetal calf serum (FCS) for further analyses. For
flow cytometry analyses, red cells were lysed from blood samples
as previously described.22 Spleens were harvested, weighed, and
dissociated in PBS with 2% FCS. Cells and RNA from the central
region of the BM, and RNA from the endosteum were isolated
from femurs as previously described.23 Inguinal and popliteal
lymph nodes draining hind legs24 were harvested and dissociated
in PBS with 2% FCS similar to spleens.
Cell counts and colony assays
Leukocytes were counted on a Sysmex KX-21 automated cell
counter. For colony-forming unit B cell (CFU-B) assays, 105 cells
were plated in 1 mL of Methocult CFU-B medium containing 10
ng/mL human interleukin (IL)-7 following manufacturer’s instruc-
tions (Stem Cell Technologies, Vancouver, Canada). Colonies of
small lymphocytes were counted after seven days culture.
CFU-C assays to test the mobilization of myeloid progenitors
were performed in methylcellulose medium containing recombi-
nant mouse granulocyte-monocyte colony-stimulating factor
(GM-CSF), Kit ligand and IL-6, as previously described.12
Quantitative real-time RT-PCR (RT-qPCR)
RNA was precipitated, DNase was treated and reverse tran-
scribed using random hexamers. qRT-PCR with CXCL12 and IL-7
were performed using Taqman probes (labeled 5’with 6-carboxy-
fluorescein (FAM) and 3’ with blackhole quencher-1 (BHQ-1)).
Oligonucleotide sequences are shown in Online Supplementary
Table S1 except for mouse G-CSF receptor (Csf3r) primers. Primers
and probe set were purchased from Applied Biosciences (set
Mm00432735_m1). All primers crossed intron-exon boundaries
and did not amplify genomic DNA in the absence of reverse tran-
scription. RNA levels were standardized by parallel RT-qPCR
using primers to the housekeeping gene b2-microglobulin.
TNF-α measurement in bone marrow fluids
At sacrifice, femurs were flushed with 1 mL ice-cold PBS, BM
cells dissociated by serial pipetting and then pelleted at 400 x g for
5 min at 4°C. BM fluids in supernatants were collected, aliquoted
and stored at -70°C until use. TNF-α protein concentration was
measured using the BD Cytometric Bead Array for mouse inflam-
matory cytokines following the manufacturer’s instructions (BD
Biosciences, Sydney, Australia) and analyzed on an LSRII flow
cytometer (BD Biosciences).
Flow cytometry
Bone marrow, blood and spleen leukocytes were pelleted at 370
x g for 5 min at 4°C and resuspended in 2.4G2 anti-CD16/CD32
hybridoma culture supernatant to block IgGFc receptors.
Measurement of B-progenitor cells were performed by staining
cell suspensions with CD11b-PECy7, NK1.1-PE, biotinylated don-
key F(ab)’2 anti-mouse-IgM with streptavidin-Pacific Blue, B220-
APCCy7, CD19-PercPCy5.5 or CD19-APC and CD43-FITC (BD
Biosciences) monoclonal antibodies. For sorting, cells were labeled
in an identical manner and sorted in medium containing 50% FCS
on an Aria cell sorter (BD Biosciences). 
Mobilization of HSPC was measured by flow cytometry using
a cocktail of anti-lineage (Lin) antibodies (CD3e, CD5, B220,
CD11b, Gr-1, CD41, Ter119), anti-Sca-1, anti-Kit, CD48 and
CD150 antibodies, as previously described.25
For apoptosis assays, BM cells were labeled as above, pelleted,
resuspended in 100 mL of annexin V binding buffer (BD
Biosciences) and incubated with APC-conjugated annexin V at
room temperature for 15 min.  Cells were then analyzed using an
LSRII flow cytometer following addition of 2 mg/mL 7-actino-
mycin D (7-AAD).
Statistical analysis
Calculations for whole body content in B-cell progenitors were
based on the assumption that one femur represents 5.6% of total
mouse BM and total volume of blood is 0.08 mL per g of body
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weight.26 Significance levels were calculated using the Student’s t-
test for colony assays, flow cytometry analyses, and RT-qPCR.
Results
G-CSF inhibits medullar B-lymphopoiesis
Adult mice were mobilized by bi-daily injections of G-
CSF for up to six days (Figure 1A) and expression of IL-7
and CXCL12 was measured in the endosteal region of the
BM by RT-qPCR (Figure 1B). TNF-α protein concentration
was directly measured in BM fluids (Figure 1C). IL-7 and
CXCL12 mRNA expression were both significantly inhib-
ited by G-CSF treatment whereas TNF-α protein concen-
tration in BM fluids increased during the first four days of
G-CSF treatment. As CXCL12 and IL-7 are B-lymphopoi-
etic cytokines27-29 and TNF-α has been reported to inhibit
B-lymphopoiesis,30 these results suggested that G-CSF
may impair B lymphopoiesis in the BM.
We next measured the number of B220+CD11b–NK1.1–
B cells in BM, blood and spleen by flow cytometry. The
frequency of these B cells in the BM declined 28-fold at
Day 6 of G-CSF treatment and progressively returned to
normal levels eight days following cessation of G-CSF
administration (Figure 2A). This decrease in medullar B
cells was not accompanied by any significant increase in
the number of B cells in blood or spleen during G-CSF
treatment (Days 0-6) (Figure 2A) although a significant
increase in blood B cells was observed at Day 10 when the
number of B cells in the BM began to recover, returning to
normal values by Day 14. Assuming that a femur repre-
sents 5.6% of total BM, and that total blood volume is pro-
portional to mouse body weight (0.08 mL/g),26 we found
that the total number of B cells in whole BM, blood and
spleen per mouse declined progressively by 60% at Day 6
of G-CSF administration and returned to baseline values
by Day 14. To further clarify whether this decline in BM B
cells was due to a halt in medullar B-lymphopoiesis or
involved relocation of some B progenitors into the spleen,
B progenitors and B cells were enumerated by flow
cytometry. B-lineage cells were gated within the side-
scatterlowCD11b-NK1.1- population as surface IgM (sIgM)–
B220+CD19-CD43+ pre-pro-B cells,
sIgM–B220lowCD19+CD43- pro-B cells, sIgM-B220+CD19+
pre-B cells, and sIgM+B220+ mature B cells, as previously
reported by Zhu et al.,10 and Hardy et al. for the specific
expression of CD43 in pre-pro-B cells31 (Figure 3A). These
analyses revealed a rapid and pronounced decline of all B-
Effect of mobilizing agents on B-lymphopoiesis
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Figure 1. Effect of G-CSF, CYP and
AMD3100 on CFU-C mobilization and
expression of IL-7, CXCL12 and TNF-α.
(A) Mobilization of CFU-C in peripheral
blood was measured at indicated time
points. Data are means±SD, 4 mice per
time point. (B) IL-7 and CXCL12 mRNA
were measured in the endosteal region
of the BM by RT-qPCR. Data are relative
to b2-microglobulin mRNA. Each dot is
the result from an individual mouse.
Bars are the average of each group. (C)
Concentration of TNF-α protein in BM flu-
ids. Each dot is the result from an indi-
vidual mouse. Bars are the average of
each group. ***P<0.001, **P<0.01, and
*P<0.05. Gray boxes on kinetics show
time period during which HSPC were





































0 2 4 6 8 10
Days
0 2 4 6 8 10
Days
0 2 4 6 8 10
Days
0 2 4 6 8 10
Days
0 3 6 9
Days after CYP
0 3 6 9
Days after CYP
0 3 6 9
Days after CYP























































cell populations in the BM, with the exception of pro-B
cells whose decline was delayed, occurring only at Day 4
of G-CSF administration (Figure 3B). Importantly,
although some pre-pro/pro/pre-B cells relocated to blood
and spleen, this did not compensate for the loss of BM B
cells and their progenitors, resulting in a net decrease in
pre-pro-B (3.5-fold), pro-B (1.7-fold), pre-B (4.6-fold), and
mature B (1.9-fold) cells on a per mouse basis for the sum
of the BM, blood and splenic compartments (Figure 3B).
These results were confirmed at the level of more primi-
tive CFU-B in functional B-cell colony assays, with a rapid
and severe decline in medullar CFU-B with only marginal
mobilization into blood and spleen (Figure 3B).
Importantly, while mature sIgM+B220+ B cells were abun-
dant in inguinal and popliteal lymph nodes, all sIgM–B220+
B-progenitor subsets were very rare (less than 1/100 of
mature B cells). Furthermore, their number did not
increase after four days of G-CSF (Online Supplementary
Figure S1), excluding the possibility that B-cell progenitors
home to lymph nodes in response to G-CSF.
To determine whether this loss in medullar B cells was
mediated by apoptosis, BM cells were stained with 7-
AAD and annexin-V (Figure 3C). Apoptosis of immature
sIgM– and mature sIgM+ B cells was in part responsible for
this collapse in medullar B-lymphopoiesis with a signifi-
cant increase in the proportion of 7-AAD+ and/or annexin-
V+ apoptotic cells in these two B-cell populations after four
days of G-CSF. Conversely, the proportion of apoptotic
BM myeloid cells was significantly decreased by G-CSF
treatment.
Blockage of TNF-α does not prevent HSPC mobilization
or arrest in B-lymphopoiesis
To determine whether the effect of G-CSF on B cells
was direct, sIgM–B220+CD19–CD43+ pre-pro-B cells,
sIgM-B220+CD19+CD43– pre-B and pro-B cells, and
sIgM+B220+ mature B cells were sorted from the BM, RNA
extracted and G-CSF receptor mRNA quantified by RT-
qPCR. G-CSF receptor mRNA were undetectable in all B-
cell populations but abundantly expressed in BM CD11b+
myeloid cells and Lin–Sca1-Kit+ myeloid progenitors
(Online Supplementary Figure S2). Therefore, in the absence
of receptor, the effect of G-CSF on B cells must be indi-
rect.
As TNF-α inhibits B-lymphopoiesis30 and is increased in
the BM during G-CSF treatment (Figure 1), we treated
mice for four days with etanercept, a human TNFR2-IgG1
Fc chimera that cross-reacts with mouse TNF-α and
inhibits endogenous soluble mouse TNF-α.21 Mice were
then mobilized with G-CSF for the last three days.
Etanercept treatment did not alter mobilization of CFU-
C, Lin-Sca1+Kit+ HSPC or Lin–Sca1+Kit+CD48–CD150+ HSC
into the blood or spleen (Online Supplementary Figure S3).
Etanercept did not prevent the loss of pre-pro-B cells or
more mature B-cell precursors in the BM following G-CSF
treatment, although it did increase the number of mature
B cells in steady-state (Online Supplementary Figure S3).
These results were confirmed in mice knocked-out for
both TNF-α and TRAIL genes. A 4-day treatment with G-
CSF also strongly reduced medullar B lymphopoiesis in
these mice (Online Supplementary Figure S4). Therefore,
I.G. Winkler et al.
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Figure 2. Comparative effect of G-CSF, CYP and AMD3100 on B cells in BM, blood and spleen. At indicated time points, SSClow CD11b– B220+
B cells were measured by flow cytometry in BM, blood and spleen. The charts on the right column show the number of B cells in total BM,
blood, spleen per mouse calculated after summation of content in BM, blood and spleen. Data are average±SD of 4 mice per time point per
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TNF-α, and TNF-α related TRAIL are dispensable to the
B-lymphopoiesis inhibition in response to G-CSF.
Overexpression of Bcl-2 rescues CFU-B and 
pre-pro-B cells in response to G-CSF
To further investigate the contribution of apoptosis in
the inhibition of B-lymphopoiesis in response to G-CSF,
we next mobilized vavBcl2 transgenic mice which over-
express the Bcl2 gene under the vav gene promoter in all
hematopoietic cells. Bcl2 is an anti-apoptotic protein nec-
essary to early B-cell development32 and mutations in Bcl2
gene are frequent in B-cell neoplasms.33-34 Overexpression
of Bcl2 in hematopoietic cells causes a pan-leukophilia, B-
cell accumulation in the spleen, evolving to follicular lym-
phoma after 40-week latency.18,35 We conducted experi-
ments in 8-week old mice that did not shown any sign of
malignancy despite a pronounced leukophilia in steady-
state (data not shown). Colony assays in the presence of
GM-CSF, Kit ligand and IL-6 showed that the number of
myeloid progenitors CFU-C in blood and spleen was more
than a degree of magnitude higher in vavBcl2 mice com-
pared to wild-type, both in steady-state and after a 4-day
course of G-CSF (Figure 4A). There was no significant dif-
ference in CFU-C content in the BM between the two
strains in steady-state or during mobilization.
B-cell subset analysis revealed that, unlike the wild-
type, there was no significant loss of pre-pro-B cells and
CFU-B in mobilized BM from vavBcl2 transgenic mice
(Figure 4B). Mobilization of pre-pro-B cells and CFU-B
into the blood was also more pronounced (Figure 4B).
Therefore, overexpression of Bcl2 rescued the loss of most
primitive B-cell progenitors in G-CSF mobilized BM. CFU-
Effect of mobilizing agents on B-lymphopoiesis
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Figure 3. G-CSF induces loss of all B-
cell subsets in the BM. (A) Gating
strategy to identify B-cell subsets
during mobilization. B-cell subsets
were defined within the SSClow
CD11b- NK1.1- B220+ population as
shown in the top two dot-plots.
Mature B cells were defined as
sIgM+ whereas immature B cells
were sIgM-. Immature B cells were
then subdivided in B220+ CD19–
CD43+ pre-pro-B cells, B220low CD19+
pro-B cells and B220+ CD19+ pre-B
cells. Typical B-cell profiles are
shown for BM from control saline
treated mice (top row) and G-CSF-
treated mice (bottom row). Note the
strong reduction of all B-cell subsets
in G-CSF-mobilized BM. (B) The
number of cells in each B-cell sub-
set (pre-pro-B, Pro-B, pre-B and
mature B cells) was measured by
flow cytometry in BM, blood and
spleen at indicated time points of G-
CSF treatment. Results per mouse
were calculated after summation of
content in BM, blood and spleen.
The number of CFU-B was measured
in B-cell colony assays. (C)
Apoptosis in BM cells was meas-
ured by flow cytometry. Cells were
considered apoptotic when they
were positive for annexin-V and/or
7-AAD. Data are average±SD of 4
mice per time-point per treatment
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B were also dramatically increased in the spleen of mobi-
lized vavBcl2 mice (Figure 4B).
Analysis of more mature B cells revealed that, although
the number of pro-B, pre-B and mature B cells was dramat-
ically decreased in the BM of mobilized vavBcl2 mice, this
loss in the BM was fully compensated by a robust mobi-
lization of these B-cell subsets into the blood.
Consequently, the total number of CFU-B, pre-pro-B, pro-
B, pre-B and mature B cells did not decrease on a per mouse
basis that included the summation of BM, blood and
spleen compartments (Figure 4B). This is in sharp contrast
to wild-type mice in which the loss of B cells in the BM
was not compensated by their number in the blood, spleen
or lymph nodes, resulting in an overall decrease of all B-cell
types on a per mouse basis (Figure 3B). Taken together,
these data show that Bcl2 overexpression rescues the arrest
in medullar B lymphopoiesis during G-CSF administration
with maintenance of pre-pro-B cell and CFU-B pools in the
BM, and redistribution of all B-cell stages from the BM into
the blood and spleen without loss in B cells.
Cyclophosphamide (CYP) and AMD3100 induce
B-cell mobilization without impairing B-lymphopoiesis
We next examined the effect of two other mobilizing
agents on medullar B-lymphopoiesis. A single dose of the
alkylating agent CYP causes rapid myelosuppression in
BM during the acute cytotoxic phase in the first three days
of administration in mice. This is followed by a robust
rebound of hematopoiesis between Days 6-8 that coin-
cides with HSPC mobilization into the blood.16,36 Total
B220+ B cells were profoundly reduced in BM, blood and
spleen at Day 3 and slowly recovered in BM and spleen
between Days 6 and 14 (Figure 2). To better understand
the effect of CYP on lymphopoiesis, B-cell precursors
were further analyzed in these three tissues following the
same gating strategy as that used in G-CSF-mobilized
mice. At Day 3, during the acute cytotoxic phase, pro-B,
pre-B and mature B cells were almost undetectable in the
BM (Online Supplementary Figure S5). Although significant-
ly reduced, detectable numbers of pre-pro-B cells
remained in the BM. At Days 6 and 8, when HSPC are
I.G. Winkler et al.
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Figure 4. Overexpression of Bcl-2 in
vavBcl2 mice rescues medullar B
lymphopoiesis during G-CSF treat-
ment. (A) CFU-C in blood, BM and
spleen were measured in colony
assays. (B) The number of cells in
each B-cell subset (pre-pro-B, Pro-B,
pre-B and mature B cells) was
measured by flow cytometry in BM,
blood and spleen at Day 6 of G-CSF
or saline treatments. Results per
mouse were calculated after sum-
mation of content in BM, blood and
spleen. The number of CFU-B was
measured in B-cell colony assays.
Data are average±SD of 4 mice per
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mobilized into the blood (Figure 1A),36 medullar B-lym-
phopoiesis was re-initiated with increased pre-pro-B, pro-
B and pre-B cells in the BM. These B cell precursors were
also robustly mobilized into the blood and spleen (Online
Supplementary Figure S5). As a result, all these B-cell precur-
sor populations rebounded from the Day 3 nadir on a per
mouse basis based on the summation of the BM, blood
and spleen compartments (Online Supplementary Figure S5).
Therefore, unlike G-CSF, HSPC mobilization in response
to CYP is not concomitant with an arrest in medullar 
B-lymphopoiesis. Importantly, we noted that B-cell matu-
ration to sIgM+ was delayed with the numbers of mature
B cells remaining low in BM, spleen and BM even ten days
after CYP injection (Online Supplementary Figure S5). As
mature B cells represent a large proportion of B cells in the
blood, this low number of mature B cells explains the per-
sistent low number of total B cells in the blood even 14
days after CYP treatment (Figure 2B).
Finally, to determine the effects of CXCR4, mice were
treated with AMD3100, a CXCR4 antagonist that blocks
the chemotactic effect of the chemokine CXCL12,37 and
tissues harvested 1 h later at the peak of HSPC mobiliza-
tion17 (Figure 1A). AMD3100 caused a slight decrease in
medullar B cells and significant B-cell mobilization into
blood and spleen (Figure 2C). A more detailed analysis of
B-cell subsets showed very robust mobilization of all B-
cell types into the blood (Online Supplementary Figure S6).
A significant proportion of pro-B, pre-B and mature B cells
had already homed to the spleen after 1 h of AMD3100
injection, demonstrating that these B cells can very rapidly
home to the spleen. There was no significant reduction in
pre-pro-B cells and pro-B cells in the BM following
AMD3100 treatment. However, the number of more dif-
ferentiated pre-B and mature sIgM+ B cells was significant-
ly reduced in the BM (Online Supplementary Figure S6)
explaining the overall reduction of B cells in the BM
(Figure 2C). Finally, AMD3100 treatment did not alter the
numbers of pre-pro-B, pro-B and mature B cells on a per
mouse basis (in BM, blood and spleen) (Online
Supplementary Figure S6). Together, these results suggest
that AMD3100 does not compromise medullar B lym-
phopoiesis and B-cell survival despite a robust mobilizing
effect on all differentiation stages of the B-cell lineage.
Discussion
G-CSF causes a rapid loss of osteoblasts on endosteal
surfaces12,16 with reduction in the transcription of both
CXCL12 and IL-7 mRNA in the endosteal region, and
increased TNF-α protein in BM fluids. This is accompa-
nied by a very pronounced reduction in the numbers of
pre-pro-B, pro-B, pre-B and sIgM+ mature B cells in the
BM. The loss of B-cell precursors in the BM is not compen-
sated by relocation to the blood, spleen or lymph nodes.
Furthermore, the proportion of apoptotic B cells increased
in the BM in response to G-CSF, a loss that was rescued by
the overexpression of the anti-apoptotic protein Bcl2. This
suggests that G-CSF blocks medullar B-lymphopoiesis by
increasing B-progenitor cell apoptosis via the mitochondr-
ial-triggered pathway. This is consistent with the observa-
tion that Bcl2 overexpression also rescues B-cell numbers
in the BM and spleen of mice deficient in BOB.1/OBF.1, a
B-cell specific transcriptional co-activator.32
This effect of G-CSF was indirect as B cells and their
progenitors do not express G-CSF receptor. A possible
candidate for mediating this indirect effect was TNF-α as:
1) TNF-α administration directly inhibits B lymphopoiesis;
and 2) inhibition of B-lymphopoiesis by LPS- or adjuvant-
induced acute inflammation are in part TNF-α depen-
dant.30 However, we have found that neither blockade of
endogenous TNF-α with etanercept nor targeted deletion
of the TNF-α or TRAIL genes prevents the arrest in B-lym-
phopoiesis caused by G-CSF. Therefore, although G-CSF
and acute inflammation38-39 both enhance myelopoiesis
and suppress B-lymphopoiesis, the mechanisms are some-
what distinct in respect to the role of TNF-α. Clearly,
cytokines other than TNF-α and TRAIL play a role in
inhibiting B-lymphopoiesis in response to G-CSF. One
possibility is lymphotoxin-α, since this cytokine is known
to alter B-cell maturation in vivo19,40 but this remains to be
investigated in relation to G-CSF. A possible mechanism
leading to increased B-cell apoptosis in the BM in response
to G-CSF could be the downregulation of both CXCL12
and IL-7 mRNA in the endosteal region. Indeed, both
CXCL1227-28 and IL-729 are indispensable to B-lym-
phopoiesis. CXCL12 and IL-7 have been reported to be
produced by separate BM stromal cells and from distinct
niches for pre-pro-B cells and pro-B cells respectively.41 An
important role of osteoblasts in regulating B-lym-
phopoiesis is suggested by expression of both IL-7 and
CXCL1211 in osteoblasts. Furthermore, deletion of the
protein Gsα gene specifically in primitive osteoprogeni-
tors and osteoblasts using Cre recombinase under the con-
trol of the osterix gene promoter (GsαosxKO mice) also
reduces the number of osteoblasts on endosteal surfaces,
and down-regulates IL-7 expression leading to impaired
medullar B lymphopoiesis with reduced numbers of pro-
B- and pre-B cells, whereas pre-pro-B and sIgM+ B cells are
unaffected in the BM of these mice.11 This phenotype is
somewhat similar to our observation in wild-type mice
mobilized with G-CSF except that G-CSF strongly
reduced pre-pro-B cells and sIgM+ B cells in addition to
pro-B and pre-B cells (Figure 3). In these GsαosxKO mice,
administration of exogenous IL-7 was also able to partially
rescue medullar B-lymphopoiesis.11 Therefore, it is excit-
ing to speculate that: 1) the attenuation of IL-7 expression
in pro-B and pre-B cell niches observed in GsαosxKO mice
mice or wild-type mice treated with G-CSF, induces apop-
tosis of IL-7-dependent pro-B and pre-B cells; and 2) that
the subsequent B-cell apoptosis can be rescued either com-
pletely by overexpression of the Bcl2 anti-apoptotic pro-
tein, or partially by administering IL-7. The main differ-
ence between GsαosxKO mice mice and G-CSF-treated wild-
type mice is that CXCL12 was down-regulated in the lat-
ter, not in the former. This may explain the pronounced
decrease in pre-pro-B cells and mature sIgM+ B cells that
was not observed in GsαosxKO mice mice.
The lesser effect of CYP on medullar B-lymphopoiesis
was unexpected as CYP also ablates osteoblasts, although
this occurs during the rebound phase between Days 6-10
following CYP administration when HSPC are mobilized
into the blood.16 The persistent absence of endosteal
osteoblasts at Days 6-10 of CYP16 did not prevent the re-
expression of IL-7 at Day 8, or the rebound in medullar B-
lymphopoiesis with the number of pro-B and pre-B cells
increasing in the BM from Day 6 and more primitive pre-
pro-B cells from Day 8 after CYP administration. This
was highly unexpected as osteoblasts have been reported
to be necessary to maintain medullar B-lymphopoiesis in
Effect of mobilizing agents on B-lymphopoiesis
haematologica | 2013; 98(3) 331
vivo.10 Of note, less primitive pro-B and pre-B cells
rebounded in the BM two days prior to pre-pro-B cells
which rebounded in the BM at Day 8 only. As pre-pro-B
cells rebounded in the spleen earlier than in the BM (Day
6 instead of Day 8), this suggests that B-lymphopoiesis re-
started from the spleen sometime between Day 3 and
Day 6 post-CYP and seeded the BM despite persistent
absence of osteoblasts. Clearly, expression of IL-7 and
CXCL12 resumed in other BM stromal cells in the
absence of osteoblasts. This is consistent with previous
observations showing that IL-7 and CXCL12 are also
expressed by distinct stromal cells away from the endos-
teum.41-42 However, it is important to note that despite the
re-expression of both IL-7 and CXCL12 and re-initiation
of medullar B-lymphopoiesis, the maturation of pre-B
cells into sIgM+ cells was still blocked at Day 10 after CYP
when osteoblasts are still absent,16 with very few sIgM+ B
cells in BM, blood and spleen.
Finally, we found that all B-cell subsets were robustly
mobilized 1 h after AMD3100 administration without inhi-
bition of CXCL12 or IL-7 expression or medullar 
B-lymphopoiesis. This is consistent with our previous obser-
vations that AMD3100 has no effect on osteoblast numbers
and expression of the osteoblast marker osteocalcin.16
Therefore, AMD3100 mobilizes B cells by directly antago-
nizing CXCR4 which is expressed by B cells,43-44 without
interfering with B-cell niches or medullar lymphopoiesis.
In conclusion, the three HSC mobilizing agents G-CSF,
CYP and AMD3100 have very distinct effects on B-lym-
phopoiesis and B-cell mobilization with: 1) G-CSF inhibit-
ing medullar B-lymphopoiesis without mobilizing B cells
in a mechanism distinct from the loss of B-lymphopoiesis
observed during inflammation or viral infections;30,38 2)
CYP mobilizing B cells but blocking their maturation into
sIgM+ B cells; and 3) AMD3100 mobilizing B cells without
affecting B lymphopoiesis. These results suggest that
blood mobilized with these three agents may have distinct
immune properties.
Finally, as G-CSF is a potent inhibitor of B-lym-
phopoiesis, it could be a useful agent to treat B-cell neo-
plasms. However, as Bcl2 overexpression is common in
and drives B-cell neoplasms, combinations of G-CSF with
Bcl2 inhibitors such as ABT-73745-47 or obatoclax48 could
efficiently target B-cell malignancies or lymphoprolifera-
tive disorders associated with Bcl2 overexpression.
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